Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Appointed director
Letter to company
Director departure
|
|
Urigen Pharmaceuticals, Inc. (URGP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2012 |
8-K
| Quarterly results |
| 09/12/2012 |
8-K
| Entry into a Material Definitive Agreement |
| 06/07/2012 |
8-K
| Form 8-K - Current report |
| 01/10/2012 |
8-K
| Form 8-K - Current report |
| 09/07/2010 |
8-K
| Form 8-K - Current report |
| 07/06/2010 |
8-K
| Form 8-K - Current report |
| 05/04/2010 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"Amendment dated April 19, 2010by and between Urigen Pharmaceuticals, Inc. and Platinum-Montaur Life Sciences, LLC",
"Certificate of designation of the relative rights and preferencesOf theSeries C Convertible Preferred Stock filed with the Secretary of State of Delaware on April 21, 2010",
"Warrant issued to Platinum-Montaur Life Sciences, LLC",
"Source: Urigen Pharmaceuticals, Inc. On Monday April 26, 2010, 9:25" |
|
| 03/03/2010 |
8-K
| Form 8-K - Current report |
| 01/15/2010 |
8-K
| Form 8-K - Current report |
| 12/31/2009 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 12/21/2009 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Consulting Agreement between Urigen Pharmaceuticals, Inc. and Oceana Therapeutics",
"Urigen & Oceana Collaborate on FDA Meeting Preparation SAN FRANCISCO, Dec. 21, 2009 -- Urigen Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101. "Oceana has expertise in developing and commercializing drugs which are delivered procedurally, including in urology," said Urigen’s CEO William J. Garner, MD. “This allows Urigen to move URG101 forward with a talented potential partner to prepare for an FDA meeting.” David S. Tierney, M.D., President and COO, Oceana Therapeutics said, “We’re excited about the potential of URG10..." |
|
| 12/07/2009 |
8-K
| Appointed a new director |
| 10/29/2009 |
8-K
| Form 8-K - Current report |
| 10/28/2009 |
8-K
| Form 8-K - Current report |
| 08/26/2009 |
8-K
| Form 8-K - Current report |
| 08/20/2009 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 07/24/2009 |
8-K
| Form 8-K -- Current report |
| 06/12/2009 |
8-K
| Appointed a new director |
| 04/29/2009 |
8-K
| Form 8-K -- Current report |
| 01/15/2009 |
8-K
| Form 8-K -- Current report |
| 12/29/2008 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Urigen Amends Its Core UCSD License for URG101 Monday December 29, 10:23 am ET SAN FRANCISCO, CA----Dec 29, 2008 -- Urigen Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, has amended its license agreement with the University of California at San Diego for intellectual property covering Urigen's URG101 program for Painful Bladder Syndrome. "In cooperation with UCSD, we have amended the annual license payments to ensure that we are in compliance with our obligations. Amending this license with UCSD is an important step in re-organizing and re-focusing our efforts to enhance shareholder value," said William J. Garner, MD, Chief Executive Officer of Urigen Pharmaceuticals. About Urigen Pharmaceuticals, Inc. ...",
"Amendment No. 2 to the License Agreement effective June 6, 2004 between the Company and the Regents of the University of California for Invention Docket Nos. SD2003-049 and SD2004-134 “Novel Intravesical Therapy for immediate symptom relief and Chronic Therapy in Interstitial Cystitis Patients" |
|
| 11/05/2008 |
8-K
| Form 8-K -- Current report |
| 08/11/2008 |
8-K
| Form 8-K -- Current report |
| 04/07/2008 |
8-K
| Termination of a Material Definitive Agreement |
| 11/27/2007 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/08/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Regulation FD Disclos... |
| 10/10/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Regulation FD Disclos... |
| 08/10/2007 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 08/06/2007 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
| 07/19/2007 |
8-K
| Completion of Acquisition or Disposition of Assets, Changes in Registrant.s Certifying Accountant, Changes in Control of Regi... |
| 06/29/2007 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointment ... |
| 05/22/2007 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 05/15/2007 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Notice of Delisting or Failure to ... |
| 04/18/2007 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
|
|
|